GnRH受体拮抗剂联合比卡鲁胺用于转移性前列腺癌术后的疗效分析

Efficacy of GnRH Receptor Antagonist Combined with Bicalutamide in Patients with Metastatic Prostate Cancer after Operation

目的 探讨促性腺激素释放激素(GnRH)受体拮抗剂联合比卡鲁胺在转移性前列腺癌术后的应用价值。方法 选取转移性前列腺癌术后患者74例,随机分为对照组和研究组,每组各37例,两组患者均行双侧睾丸切除术,对照组术后给予比卡鲁胺治疗,研究组在对照组基础上给予GnRH受体拮抗剂治疗,两组均随访6个月,统计并比较两组临床疗效、不良反应发生率及治疗前、治疗后1、3、6个月血清前列腺特异性抗原(PSA)水平。结果 研究组总有效率89.19%高于对照组67.57%,差异有统计学意义(χ^2=4.103,P<0.05);治疗后1、3、6个月PSA水平均显著低于治疗前(P<0.05),且研究组PSA水平低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(χ^2=0.352,P>0.05)。结论 GnRH受体拮抗剂联合比卡鲁胺应用于转移性前列腺癌术后可提高治疗效果,显著降低机体PSA水平,且安全性高。

Objective To explore the value of gonadotropin- releasing hormone (GnRH) receptor antagonist combined with bicalutamide in the treatment of metastatic prostate cancer. Methods 74 patients with metastatic prostate cancer were randomly divided into control group and study group,with 37 cases in each group.Two groups underwent bilateral orchiectomy.The control group received routine treatment and nursing after operation.The study group received GnRH receptor antagonist plus bicalutamide on the basis of the control group.The two groups were followed up for 6 months.The clinical efficacy,incidence of adverse reactions and serum prostate specific antigen (PSA) levels before treatment,1,3 and 6 months after treatment were compared between the two groups. Results The total effective rate of the study group(89.19%) was higher than that of the control group(67.57%)( P <0.05),and the difference was statistically significant (χ 2=4.103,P <0.05).The PSA levels at1,3,and 6 months after treatment were significantly lower than those before treatment ( P <0.05),and the PSA level in the study group was lower than that in the control group ( P <0.05).There was no significant difference in the incidence of adverse reactions between the two groups (χ^2=0.352,P>0.05). Conclusion GnRH receptor antagonist combined with bicalutamide can improve the therapeutic effect of metastatic prostate cancer after operation,significantly reduce the body's PSA level,and has high safety.